Table 3.
Index GLP-1 RA persistence and first modification at 6 months post-index and during overall follow-up
| Variable | All GLP-1 RA (n = 932) | Dulaglutide (n = 612) | Liraglutide (n = 271) |
|---|---|---|---|
| Persistencea, % (95% CI) | |||
| 6 months | 80.5 (77.8–83.0) | 81.9 (78.6–84.8) | 79.7 (74.4–84.3) |
| 12 months | 66.2 (63.1–69.5) | 70.7 (67.0–74.6) | 60.0 (54.2–66.4) |
| 18 months | 51.6 (47.7–55.9) | 65.4 (61.0–70.1) | 30.4 (24.3–38.1) |
| Duration of persistencea, days, median (95% CI) | 600 (526.0–NC) | NC | 440 (396.0–484.0) |
| Any first index treatment modificationb, n (%) | |||
| 6 months | 274 (29.4) | 173 (28.3) | 79 (29.2) |
| Overall follow-up | 507 (54.4) | 293 (47.9) | 183 (67.5) |
| First discontinuationc, n (%) | |||
| 6 months | 148 (15.9) | 94 (15.4) | 43 (15.9) |
| Overall follow-up | 279 (29.9) | 145 (23.7) | 118 (43.5) |
| First switchd, n (%) | |||
| 6 months | 32 (3.4) | 16 (2.6) | 11 (4.1) |
| Overall follow-up | 50 (5.4) | 22 (3.6) | 21 (7.7) |
| First augmentatione, n (%) | |||
| 6 months | 95 (10.2) | 64 (10.5) | 25 (9.2) |
| Overall follow-up | 179 (19.2) | 127 (20.8) | 44 (16.2) |
CI confidence interval, NC not calculable, GLP-1 RA glucagon-like peptide-1 receptor agonist
aPersistence was the duration of index GLP-1 RA therapy from initiation to discontinuation or switch
bAny first index GLP-1 RA treatment modification included the first post-index discontinuation, switch, or augmentation
cDiscontinuation was an absence of any prescription for the index GLP-1 RA for > 60 days since the previous visit
dSwitch was the prescription of a new antidiabetic medication within 30 days before or after discontinuation of the index GLP-1 RA
eAugmentation was the prescription of a new antidiabetic medication > 30 days before index GLP-1 RA discontinuation or the end of the follow-up period, whichever came first